Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Idea to Innovation

Université de Montréal

$124,995.00

A small and sensitive SPR instrument for chemotherapy monitoring

FY 2012-13

Summary
Sensitive tools for rapid and reliable quantification of chemotherapy agents may improve treatment of leukemia and bone marrow transplant in adults undergoing chemotherapy. In particular, methotrexate (MTX) is a widely employed cytotoxic agent that offers major therapeutic benefits despite severe side effects. There is a clinical need for regular monitoring of the concentration of MTX during the course of a chemotherapy treatment, to adjust the dose for each patient and thus maximize efficacy while minimizing side effects. Frequent monitoring insures optimal dosage for patient's safety and treatment efficacy. Surface plasmon resonance (SPR) is commonly used as an optical technique for studying molecular recognition, and could serve to quantify drugs. However, current commercial SPR instruments are bulky, expensive and lack sensitivity in biological media, precluding their application in clinical settings; furthermore, instrument design restricts analysis to a laboratory. The latest breakthroughs in materials science and plasmonic instrument design exploit microhole arrays to enhance SPR response, and peptide surface chemistry to overcome the surface-fouling limitations, which typically plague commercial SPR instrumentation in presence of crude biofluids. We have applied these novel concepts of SPR technology to monitor the concentration of various molecules. We propose to integrate this label-free, fast, reliable, sensitive and effective technology to monitor MTX levels in the serum of chemotherapy patients. To achieve this objective, the SPR device will be prototyped as a functional platform that will be validated with actual serum samples from patients undergoing chemotherapy, in collaboration with a clinician biochemist, specialist of MTX dosing in hospital environment. The concentration of MTX obtained by SPR sensing in patients' sera will be compared to standard techniques, such as fluorescence polarization immunoassay (FPIA) and LC-MS/MS, to validate the SPR sensing technology. This application of the novel SPR device is thus designed to rapidly enhance patient care by providing clinicians a faster, sensitive and portable tool to perform the analysis of MTX during ongoing chemotherapy treatments.
Program
Idea to Innovation
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
430487-2012
Name nom
Masson, JeanFrancois
Department département
Chimie
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2012
Award amount
124995
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
3505
Research subject group en
Analytical chemistry
Research subject group fr
Chimie analytique
Research subject en
Analytical spectroscopy
Research subject fr
Spectroscopie analytique
Partie
1
Nb partie
1
Application title
A small and sensitive SPR instrument for chemotherapy monitoring
Keyword
NSERC
Application summary
Sensitive tools for rapid and reliable quantification of chemotherapy agents may improve treatment of leukemia and bone marrow transplant in adults undergoing chemotherapy. In particular, methotrexate (MTX) is a widely employed cytotoxic agent that offers major therapeutic benefits despite severe side effects. There is a clinical need for regular monitoring of the concentration of MTX during the course of a chemotherapy treatment, to adjust the dose for each patient and thus maximize efficacy while minimizing side effects. Frequent monitoring insures optimal dosage for patient's safety and treatment efficacy. Surface plasmon resonance (SPR) is commonly used as an optical technique for studying molecular recognition, and could serve to quantify drugs. However, current commercial SPR instruments are bulky, expensive and lack sensitivity in biological media, precluding their application in clinical settings; furthermore, instrument design restricts analysis to a laboratory. The latest breakthroughs in materials science and plasmonic instrument design exploit microhole arrays to enhance SPR response, and peptide surface chemistry to overcome the surface-fouling limitations, which typically plague commercial SPR instrumentation in presence of crude biofluids. We have applied these novel concepts of SPR technology to monitor the concentration of various molecules. We propose to integrate this label-free, fast, reliable, sensitive and effective technology to monitor MTX levels in the serum of chemotherapy patients. To achieve this objective, the SPR device will be prototyped as a functional platform that will be validated with actual serum samples from patients undergoing chemotherapy, in collaboration with a clinician biochemist, specialist of MTX dosing in hospital environment. The concentration of MTX obtained by SPR sensing in patients' sera will be compared to standard techniques, such as fluorescence polarization immunoassay (FPIA) and LC-MS/MS, to validate the SPR sensing technology. This application of the novel SPR device is thus designed to rapidly enhance patient care by providing clinicians a faster, sensitive and portable tool to perform the analysis of MTX during ongoing chemotherapy treatments.
Université de Montréal - $124,995 Grant (2012-13) | Canada Spends